Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2015 | Pages:
68 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Hepatic (Liver) Metastasis - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Hepatic (Liver) Metastasis - Pipeline Review, H2 2015', provides an overview of the Hepatic (Liver) Metastasis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Hepatic (Liver) Metastasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatic (Liver) Metastasis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Hepatic (Liver) Metastasis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Hepatic (Liver) Metastasis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Hepatic (Liver) Metastasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Hepatic (Liver) Metastasis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hepatic (Liver) Metastasis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hepatic (Liver) Metastasis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents
2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Hepatic (Liver) Metastasis Overview 8 Therapeutics Development 9 Pipeline Products for Hepatic (Liver) Metastasis - Overview 9 Pipeline Products for Hepatic (Liver) Metastasis - Comparative Analysis 10 Hepatic (Liver) Metastasis - Therapeutics under Development by Companies 11 Hepatic (Liver) Metastasis - Therapeutics under Investigation by Universities/Institutes 12 Hepatic (Liver) Metastasis - Pipeline Products Glance 13 Clinical Stage Products 13 Early Stage Products 14 Hepatic (Liver) Metastasis - Products under Development by Companies 15 Hepatic (Liver) Metastasis - Products under Investigation by Universities/Institutes 16 Hepatic (Liver) Metastasis - Companies Involved in Therapeutics Development 17 Amgen Inc. 17 BioCancell Ltd 18 CytRx Corporation 19 Digna Biotech, S.L. 20 Gradalis Inc. 21 Incuron, LLC 22 Novartis AG 23 Phosplatin Therapeutics LLC 24 Targetome 25 Hepatic (Liver) Metastasis - Therapeutics Assessment 26 Assessment by Monotherapy Products 26 Assessment by Target 27 Assessment by Mechanism of Action 29 Assessment by Route of Administration 31 Assessment by Molecule Type 33 Drug Profiles 35 Antibodies to Inhibit FRMD4A for Oncology - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 BC-821 - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 cancer vaccine - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Cell Therapy to Target CEA for Oncology - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Cyt-HiPoA - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 DB-02901 - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 mepacrine - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 MS-417 - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 pasireotide - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 PT-112 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 Recombinant Protein to Antagonize IGF-1R for Liver Metastasis and Breast Cancer - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 talimogene laherparepvec - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 TGM-002 - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 TGM-003 - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 Hepatic (Liver) Metastasis - Recent Pipeline Updates 55 Hepatic (Liver) Metastasis - Dormant Projects 64 Hepatic (Liver) Metastasis - Discontinued Products 65 Hepatic (Liver) Metastasis - Product Development Milestones 66 Featured News & Press Releases 66 Apr 16, 2014: Cleveland BioLabs Announces the Successful Completion of a Phase 1 Study of CBL0102 66 Appendix 67 Methodology 67 Coverage 67 Secondary Research 67 Primary Research 67 Expert Panel Validation 67 Contact Us 67 Disclaimer 68
List of Tables
Number of Products under Development for Hepatic (Liver) Metastasis, H2 2015 9 Number of Products under Development for Hepatic (Liver) Metastasis - Comparative Analysis, H2 2015 10 Number of Products under Development by Companies, H2 2015 11 Number of Products under Investigation by Universities/Institutes, H2 2015 12 Comparative Analysis by Clinical Stage Development, H2 2015 13 Comparative Analysis by Early Stage Development, H2 2015 14 Products under Development by Companies, H2 2015 15 Products under Investigation by Universities/Institutes, H2 2015 16 Hepatic (Liver) Metastasis - Pipeline by Amgen Inc., H2 2015 17 Hepatic (Liver) Metastasis - Pipeline by BioCancell Ltd, H2 2015 18 Hepatic (Liver) Metastasis - Pipeline by CytRx Corporation, H2 2015 19 Hepatic (Liver) Metastasis - Pipeline by Digna Biotech, S.L., H2 2015 20 Hepatic (Liver) Metastasis - Pipeline by Gradalis Inc., H2 2015 21 Hepatic (Liver) Metastasis - Pipeline by Incuron, LLC, H2 2015 22 Hepatic (Liver) Metastasis - Pipeline by Novartis AG, H2 2015 23 Hepatic (Liver) Metastasis - Pipeline by Phosplatin Therapeutics LLC, H2 2015 24 Hepatic (Liver) Metastasis - Pipeline by Targetome, H2 2015 25 Assessment by Monotherapy Products, H2 2015 26 Number of Products by Stage and Target, H2 2015 28 Number of Products by Stage and Mechanism of Action, H2 2015 30 Number of Products by Stage and Route of Administration, H2 2015 32 Number of Products by Stage and Molecule Type, H2 2015 34 Hepatic (Liver) Metastasis Therapeutics - Recent Pipeline Updates, H2 2015 55 Hepatic (Liver) Metastasis - Dormant Projects, H2 2015 64 Hepatic (Liver) Metastasis - Discontinued Products, H2 2015 65
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
